Market Research Report
North America Biochips Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||603657|
|Published||Content info||92 Pages
Delivery time: 1-2 business days
|North America Biochips Market Forecast 2019-2027|
|Published: March 9, 2019||Content info: 92 Pages||
North America biochips market is expected to evolve with 20.89% CAGR over the forecast period of 2019-2027. Between these years, the market revenue is expected to increase from $xx million in 2018 and reach $x million by 2027. Biochips have a crucial requirement in molecular diagnostics, and their application in point-of-care diagnosis is expected to facilitate the development of personalized medicines.
Biochip has several applications in the field of medicine, biosciences, biotechnology, and molecular biology. In the medical industry, biochips are mostly used for drug discovery and for producing biomarkers. Investments by organizations like DARPA, NIH and the FDA to speed up the development of biochips in the U.S is acting as a major boosting factor for the market. Also, several key companies in this region are investing heavily in biochips technology.
On the other hand, venture capital funding by Turnstone Biologics to improve the R&D activities in the Canadian biotechnology sector, combined with the rising healthcare expenditure is expected to drive the growth across the Canada biochip market over the forecast period.
Noted companies in this market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Cybrdi Inc., Agilent Technology Inc., Cepheid Inc., IMGENEX, Biochain Institute Inc., Illumina Inc., Merck GmbH, Fluidigm Corporation, OriGene Technologies Inc., bioMerieux SA, Samsung Electronics Inc., PerkinElmer Inc. and Gamida for Life Group amongst others.